ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 253 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,110 | -38.7% | 10,112 | -24.5% | 0.00% | -33.3% |
| Q2 2023 | $89,881 | +26028.2% | 13,395 | -65.6% | 0.00% | -72.7% |
| Q1 2023 | $344 | +5633.3% | 38,978 | +4485.6% | 0.01% | – |
| Q4 2022 | $6 | -100.0% | 850 | -95.8% | 0.00% | -100.0% |
| Q3 2022 | $143,000 | +376.7% | 20,114 | +437.1% | 0.00% | +100.0% |
| Q2 2022 | $30,000 | -89.7% | 3,745 | -82.0% | 0.00% | -66.7% |
| Q1 2022 | $290,000 | +1160.9% | 20,840 | +2460.2% | 0.00% | – |
| Q4 2021 | $23,000 | -51.1% | 814 | -40.8% | 0.00% | -100.0% |
| Q3 2021 | $47,000 | -87.4% | 1,374 | -84.9% | 0.00% | -90.0% |
| Q2 2021 | $372,000 | +530.5% | 9,108 | +524.3% | 0.01% | +900.0% |
| Q1 2021 | $59,000 | -83.0% | 1,459 | -75.1% | 0.00% | -90.9% |
| Q4 2020 | $347,000 | +638.3% | 5,860 | +501.6% | 0.01% | +1000.0% |
| Q3 2020 | $47,000 | -39.7% | 974 | -39.4% | 0.00% | -66.7% |
| Q2 2020 | $78,000 | +3800.0% | 1,606 | +2874.1% | 0.00% | – |
| Q3 2019 | $2,000 | – | 54 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |